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ABSTRACT 
Background: Autism is a complex psychiatric disorder characterized by three core symptoms, 
i.e.  impairments  in  social  interaction,  restricted  patterns  of  behavior  and  impairments  in 
communication.  In the framework of the  “opioid excess  theory”, the disorder symptoms  are 
compared  to  the  behavioral  effects  of  opiates.  Based  on  this,  a  possible  nutritional  basis  of 
autism has been proposed, hypothesizing that certain food proteins such as gluten and casein can 
be transformed to opioid peptides during digestion. These peptides might eventually be able to 
enter the blood stream and act upon the central nervous system. As a consequence, a diet low in 
such proteins has been hypothesized to ameliorate the behavioral symptoms of autistic children. 
 
Objective: The scope of this review was to analyze the effects of gluten-free and casein-free 
(GFCF) diets on children with autism, as well as to provide information concerning additional 
aspects related to the GFCF diet in autism.  
 
Methods: A literature search was conducted including scientific publications up until December 
2013. Search results were screened for any kind of GFCF dietary intervention as well as surveys 
dealing with GFCF as a treatment for autism.  
 
Results: A review of survey data shows that up to 25 % of parents of affected children report on 
current use of a GFCF diet. The majority of identified studies evaluating GFCF diet outcomes 
failed to meet basic methodological standards of interventional science. Comparison of study 
results did not show any clear-cut results, with a substantial proportion of studies failing to show 
any positive dietary effect. The results of more sophisticated trials were far from equivocal and 
the studies differed by many methodological aspects. Some variables such as information source 
and trial duration seemed to affect outcome.   Functional Foods in Health and Disease 2014; 4(8):349-361                                                            Page 350 of 361 
 
 
 
Conclusions: Evidence for the effectiveness of the GFCF diet in the treatment of autism is 
sparse. Rigorous scientific evaluations partly failed to confirm therapeutic effects of the GFCF 
diet. These and other negative results related to the opioid excess theory weaken the underlying 
rationale for GFCF diet use. Nevertheless, more sophisticated investigations should be conducted 
in order to identify possible benefits and harms of such a dietary approach. 
 
Key words:  gluten-free and casein-free diet, opioid excess  theory, autism, autistic spectrum 
disorder, therapeutic effects, evidence base, prevalence of use 
 
 
Autism and the Quest for Etiology: A Case for Nutrition? 
Autism is a complex psychiatric disorder of childhood and adolescence [1]. According to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5; [2]) autism is characterized by 
three core symptoms, i.e. impairments in social interaction, restricted patterns of behavior and 
impairments in communication, The disorder has been shown to occur in approximately 0.2 % of 
child and adolescent populations. Prevalence estimates seem to have risen over the last two 
decades [3]. Prevalence estimates for autistic disorder before 1987 did not exceed 0.07 %, while, 
for reasons as yet unknown, all studies published since 2000 have consistently shown higher 
rates (range 0.07 to 0.4 %). While the increase in prevalence might be attributed to a concomitant 
rise in the incidence of the disorder, other factors such as changes in the concepts and diagnostic 
criteria  as  well  as  a  growing  awareness  within  Western  societies  have  been  suggested  as 
alternative  explanations  [3].  Risk-inducing  environmental  agents  and  the  potential  role  of 
nutrition have been discussed in the context of a gene-environment interaction [see 4]. From this 
point of view, an unbalanced diet might be able to induce biological vulnerability by itself or an 
otherwise  balanced  diet  might  disturb  the  organism’s  homeostasis  in  the  case  of  metabolic 
insufficiency [4]. The question of whether or not such an explanatory model can be put forward 
is a matter of ongoing research and debate [5]. 
Etiological  accounts  of  autism  emphasize  biological  factors  associated  with  organism 
(genes) and environment (e.g. exposure to neurotoxic agents) and seek to relate the influences of 
these factors to biomarkers of brain and organismic function [1, 6, 7]. Potential biomarkers of 
autism include structural brain abnormalities (e.g. increased brain volumes, especially in frontal 
cortex, cerebellum and amygdala), functional brain abnormalities (e.g. disconnectivity of cortical 
structures  with  more  asynchrony  in  activity,  abnormal  levels  of  neurotransmitters  and 
neuropeptides),  systemic  indicators  related  to  metabolism  (e.g.  indicators  of  mitochondrial 
dysfunction,  abnormal  urinary  excretion  of  organic  acids)  and  indicators  of  an  increased 
dysregulation of immune functions [6]. These findings are complemented by the confirmation of 
the  disorder’s  association  with  genes  related  to  cell  structure  and  function,  neuronal 
development, synaptic formation and with genes involved in neurotransmission [6]. There are 
also  indications  for  a  heightened  prevalence  of  autism  following  exposure  to  certain 
environmental agents such as pesticides and solvents, which could affect brain development [6]. 
The search for biomarkers of autism has led to inconclusive results [7]. Autism is likely to Functional Foods in Health and Disease 2014; 4(8):349-361                                                            Page 351 of 361 
 
 
represent a highly complex disorder with multiple etiologies and current treatment approaches to 
autism are therefore symptomatic [1]. 
 
Opioid excess theory and the GFCF diet 
No  definitive  biomarkers  of  autism  have  as  yet  been  identified  [7]  and  several  different 
etiological hypotheses have been proposed. The “opioid excess theory” by Panksepp [8] draws 
parallels between the disorder’s symptoms and the acute behavioral effects of opiates and links 
the disorder to an increased activity in the endogenous opioid system. Based on this proposal, 
Reichelt  et  al.  [9,  10]  were  able  to  demonstrate  a  possible  nutritional  link  to  autism  and 
hypothesized that certain food proteins such as gluten and casein can be transformed to opioid 
peptides  during  digestion.  These  peptides  might  be  metabolized  insufficiently  and  after 
accumulation enter the blood circulation through a “leaky gut” due to an increased permeability 
of the intestinal membrane [11]. After crossing the blood-brain barrier they may act directly 
upon  the  central  nervous  system  [12].  As  autism  is  conceptualized  as  a  metabolic  disorder 
according to this hypothesis, an increase in urinary levels of these opioid peptides might be a 
biomarker of the disorder. A diet low in the above mentioned proteins was hypothesized to 
normalize the urinary peptide levels (UPL) and hence ameliorate the behavioral symptoms of 
affected children [9, 12]. 
Studies investigating the urinary profiles of autistic populations were able to show increased 
levels of certain peptides [9, 10, 13-17]. In addition, some authors reported reductions in these 
peptide  levels  and  an  amelioration  of  autistic  symptoms  following  the  implementation  of  a 
gluten-free  and  casein-free  diet  (GFCF  diet)  [13,  15,  16].  These  findings  have  lent  some 
scientific credibility to the etiological account underlying the GFCF diet and advanced the diet’s 
popularity.  
 
GFCF diet – Current Status and Scope of the Review 
Several intervention studies have investigated the effects of a GFCF diet on autistic symptoms. 
Some of these investigations were summarized in a Cochrane review by Millward et al. [18] who 
included only two small randomized controlled trials in their evaluation and found mixed results 
concerning dietary effects. Mulloy et al. [19, 20] concluded on the basis of 14 studies that the 
findings  were  contradictory  and  inconclusive,  the  methods  used  were  diverse  and  hardly 
comparable and the methodological quality of studies was very limited. They also emphasized a 
possible measurement bias in many studies that relied on subjective ratings of parents not blind 
to treatment condition. Mulloy et al. [19, 20]  therefore suggested the use of GFCF diets only in 
individuals with food intolerance or allergies related to gluten and/or casein. Since the review’s 
publication,  another  two  dietary  intervention  studies  involving  the  GFCF  diet  have  been 
published [21, 22].  
The aim of the present review is to analyze the effects of gluten-free and casein-free (GFCF) 
diets on children with autism on the basis of scientific literature concerning dietary effects on 
different outcome measures. Guidelines for quality assessment and integration of evidence across 
methodologies were used [23]. Additional aspects related to the GFCF diet in autism (prevalence 
of use, possible harmful effects) were also assessed.  
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Methods  
A  literature  search  was  conducted  using  PubMed,  Medline,  ERIC  and  Google  Scholar  and 
including scientific articles published up until December 2013. The search terms used in order to 
identify relevant articles included combinations of the following: “gluten”, “casein”, “gliadine”, 
“gluten-free”, “casein-free”, “GFCF”, “diet”, “dietary”, “intervention”, “(case) study”, “trial”, 
“autism”,  “autistic”  “autistic  disorder”,  “Asperger”,  “autistic  spectrum  disorder”,  “ASD”, 
“child”, “adolescent”, adult”, “complementary and alternative medicine” “CAM” and “survey”. 
Search  results  were  screened  for  relevant  articles  involving  humans  and  any  kind  of  GFCF 
dietary intervention as well as surveys dealing with GFCF as treatment for autism. A total of 18 
dietary intervention studies and another 11 survey studies were identified and included. Four 
studies investigating possible harmful effects of the GFCF diet could be identified. In the present 
review, biochemical analyses such as the assessment of urinary peptide levels or the analysis of 
intestinal permeability were not included.  
Dietary intervention studies were evaluated regarding the level of evidence (weak, adequate, 
strong)  according  to  the  methodological  guidelines  by  Reichow  et  al.  [23].  These  authors 
published an evaluative method especially suited for the evaluation of intervention studies in 
autism. This method allows the integration of evidence across different kinds of outcome studies 
(single  case  vs.  group  research  studies)  based  on  an  evaluation  of  specified  methodological 
quality indicators thought to be essential for each kind of research design [23].  
 
Results of Prevalence Studies 
In 11 surveys attempting to assess the prevalence of the GFCF diet in autism spectrum disorder 
(ASD) populations, this diet was one of several treatment options. The studies were conducted to 
investigate the popularity of complementary and alternative medicine (CAM) treatment in ASD 
populations. These studies indicated a current use of GFCF diets in 8-32 % of families and a 
lifetime use in 20-50 % of families [24-35]. These studies show that parents frequently report the 
use of multiple CAM treatments including dietary treatments. These treatments include dietary 
supplementation with vitamins or minerals and specific forms of diet (Feingold diet, sugar free, 
GFCF etc.), of which the GFCF diet appears to be the most prominent [e.g. 24, 27]. Any clinical 
investigation attempting to elucidate the efficacy of a specific treatment modality should control 
for the use of these CAM treatments. For example, Green et al. [27] showed that parents report a 
current use of a mean of seven different treatment modalities (including CAM) for their children. 
The high number of different treatment options was confirmed by some [30, 35] but not all [32] 
studies and should be assessed more thoroughly using various national and socio-demographic 
levels. As there are indications that the parents of both more severe and younger cases of ASD 
use CAM treatments more frequently, it is obvious that scientific investigations need to assess 
and control for these alternative treatments and their potential effects regarding ASD symptoms. 
In regard to effects on ASD symptoms, only a subset of survey studies assessed parental 
perceptions  of  GFCF  dietary  effects  [24,  28,  29,  36].  These  studies  found  positive  effects 
reported by 41-69 % of parents, when categorical answers were required. A recent UK survey 
study [35] asked parent and expert groups about their experiences and perceptions regarding the 
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treatment modalities and more than 80 % reported some kind of dietary intervention (GFCF diet 
in 29 %) for their child. When asked about the effects of the GFCF diet on various symptom 
domains, 20-29 % of the parents reported significant improvements (on a dimensional Likert-
type  answer  scale)  on  the  ASD  core  dimensions.  However,  marked  improvements  of  their 
children regarding gastrointestinal symptoms and concentration/attention were reported by 54 % 
and 42 % of parents, respectively [35]. This finding, i.e. the more pronounced dietary effect on 
comorbid problems, is supported by a survey by Pennesi and Klein [33] who found that parents 
reported  more  positive  effects  of  a  GFCF  diet  when  their  child  showed  gastrointestinal 
symptoms or signs of allergy. This finding suggests that there might be a subset of children with 
ASD who could benefit from a GFCF diet. This requires further exploration and needs to be 
validated by clinical observations in addition to parents’ reports. 
In summary, the above mentioned results show that the GFCF diet is a CAM treatment 
option used by approximately 25% of families with children diagnosed with ASD. Furthermore, 
the diet is perceived by the majority of parents to have positive effects on various aspects of the 
children’s functioning. There are indications that it may not be the core dimensions of autistic 
symptomatology that are influenced most effectively by the diet. This point deserves further 
consideration  in  dietary  intervention  studies  designed  for  the  identification  of  moderating 
variables. Future prevalence surveys should be conducted with a stronger focus on comparability 
of results  across studies  in  order to  allow for  the  analysis  of trends  in  the use of treatment 
options. 
 
Results of Case Studies 
A total of eight published case studies, including anecdotal case reports and studies using a more 
or less experimental research design, attempted to establish a causal role of gluten/casein in 
autism [21, 37-43]. Not a single study was conducted with adequate scientific rigor and the 
results  of  these  studies  can  be  regarded  as  weak  evidence  at  best.  None  of  the  studies 
implemented an experimental control meeting the criteria by Reichow et al. [23]. Two studies 
[40, 43] established an adequate measurement baseline for at least some of the measures. All but 
two studies [37, 38] found evidence of positive dietary effects for at least some of the measures 
assessed, e.g. physical development, autistic symptomatology or cognitive skills. The two studies 
providing null results differed from most of the other studies by two aspects, i.e. trial duration 
and kind of outcome measure. The experimental condition in these studies was implemented no 
longer than about one week which was short compared to the other studies with observation 
periods of up to several years. Another difference is the use of different outcome measures, 
namely  behavioral  observations  and  the  use  of  objective  coding  schemes.  The  dependent 
measures were thus assessed by persons less closely related to the children than parents. The two 
studies with null results were the case studies meeting the largest number of quality indicators 
within this group of studies (6 and 7 out of 12 indicators). Another problem of two case studies 
using standardized testing procedures [42, 43] relates to an inadequate use of test/measurement 
data, i.e. the calculation of mental age scores from raw data [43] or the use of raw data itself [42] 
in  order  to  determine  treatment  progress.  This  procedure  might  seem  feasible  in  short-term 
evaluations of treatment effects or in the adult age range. However, in long-term evaluations and Functional Foods in Health and Disease 2014; 4(8):349-361                                                            Page 354 of 361 
 
 
in the age ranges covered by the published case studies of GFCF dietary effects (3-12 years of 
age), every attempt should be made in order to control for time or maturational effects. This 
could be achieved by using well-standardized and instruments, which allow the calculation of 
age-sensitive standard scores (e.g. percentile ranks). Another relevant aspect relates to parents as 
source of information. Each of the 6 studies showing at least some beneficial dietary effects used 
parents as informants on their children’s autistic behavior symptoms. This point deserves further 
consideration and future case studies should implement observational measures, standardized test 
procedures and clinician-ratings as complementary measures of dietary effects. 
In summary, evidence concerning therapeutic effects of a GFCF diet, as provided by single 
case studies, is very weak. The studies are hampered by many and mainly basic methodological 
flaws which do not allow any clear-cut interpretation of their results. While six of the eight 
identified studies were able to show at least some positive effects of the GFCF diet, two studies 
using behavioral observations  as  sole dependent  measure were  unable  to  show clear  dietary 
effects [37, 38]. Future case studies of GFCF dietary effects should use a more sophisticated 
research  design,  at  least  by  establishing  a  reliable  measure  baseline  which  can  be  used  to 
evaluate the effects following the diet. This relates to both behavioral observations and the data 
of standardized developmental testing procedures. Potential dietary effects on these measures 
(e.g.  changes  in  percentile  ranks)  should  be  compared  with  parental  reports  of  changes  in 
problem behaviors and other symptoms. Parental ratings may be complemented by judgments of 
clinicians in order to strengthen the assessment. Inter-observer agreement is another important 
scientific criterion [23] when attempting to find evidence of the effects of the GFCF diet. It 
should be noted, that the observational studies [37, 38, 40] were the only ones using this kind of 
quality evaluation. All the observational studies were conducted in institutional settings and the 
ecological validity of the results remains therefore to be established. 
 
Results of Group Studies 
A total of 10 group studies were found in the published literature. One of these studies [44] can 
be  dismissed  as  unscientific  due  to  unclear  definitions  of  improvement  and  descriptions  of 
information  sources.  Another  six  group  studies  [13,  15,  16,  45-50]  were  conducted  without 
adequate scientific rigor and could therefore provide only weak evidence concerning potential 
effects of a GFCF dietary modulation. With the exception of one study [45, 46], all of these 
studies found at least some positive effects of a GFCF dietary modulation concerning autistic 
symptoms, cognitive and language skills, motor problems or gastrointestinal symptoms. Three 
studies were conducted with more scientific rigor and provided an adequate level of scientific 
evidence [22, 51-54]. Two of these studies [22, 51] showed null results regarding dietary effects, 
while the remaining study [54] provided mixed evidence for positive dietary effects on several 
autistic features and other behavioral symptoms.  
A  problematic  aspect  of  the  group  studies  was  the  inadequate  operationalization  of  a 
comparison condition, i.e. (1) the use of no control procedures at all [13, 15, 16, 44], (2) the use 
of control groups for only parts of the investigated aspects or subsets of the sample [48] or (3) 
the neglect of other relevant variables such as the control for additional treatments [22, 47, 49, 
51,  54].  Only  two  studies  involving  behavioral  observations  formally  assessed  interobserver Functional Foods in Health and Disease 2014; 4(8):349-361                                                            Page 355 of 361 
 
 
agreement  [22,  51],  while  another  two  studies  correlated  different  measures  in  order  to 
investigate  the  validity  of  study  results  [13,  48].  Only  the  three  studies  of  adequate  report 
strength did try to ensure blindness of raters at least for some of the dependent measures [22, 51, 
54]. Only four of the studies explicitly stated control procedures to ensure the fidelity of diet 
implementation throughout the study period [15, 16, 22, 51, 54], two of these studies had the 
shortest trial duration of all the group studies (~3 months). Some studies did not even report the 
adequate  use  of  statistical  tests,  either  using  none  [44],  using  inadequate  tests  [13]  or  not 
presenting sufficient information as to the adequate use of the tests [46, 48, 51, 54]. Another 
problem was the use of parental ratings for the assessment of dietary effects. 
 
Summary of Intervention Study Results 
The evaluation of GFCF dietary trials is complicated by various methodological flaws in the 
majority of the published reports. More sophisticated trials with single case or group research 
designs provided either mixed or null results regarding dietary effects [22, 37, 38, 51, 54]. These 
findings might lead to the rejection of the GFCF diet in the treatment of autism. However, the 
diet durations in four of these studies were among the shortest of the published studies (from 4 
days to 3 months) and these methodological differences might account for the results. Almost all 
of the studies with trial durations of 12 months or longer found some indications of positive 
developmental change in the dependent measures assessed. However, most of these “positive” 
studies did not control for alternative explanations such as the effects of additional treatments, 
maturational effects etc. Evidence-based practice according to the guidelines of Reichow et al. 
[23] requires at least three independent single case studies or two independent group research 
studies conducted with at least adequate report strength and each showing the effectiveness of 
the respective treatment. As none of the single case studies showed adequate report strength and 
only one of the three group studies with adequate report strength showed some positive (though 
mixed) results regarding GFCF dietary effects, the diet itself cannot even be judged as promising 
according to these guidelines. 
In summary, the evidence of the GFCF diet’s effectiveness in the treatment of autism is too 
sparse  to  draw  any  firm  conclusion.  Future  studies  need  to  be  performed  with  more 
methodological rigor and be of longer duration in order to be judged as providing adequate or 
even strong scientific evidence. Furthermore, outcome measures should not be solely based on 
parental ratings, but include clinical expert ratings as well as naturalistic behavioral observations. 
 
Risk Studies of the GFCF Diet 
The studies of potential harmful effects of a GFCF diet in children with autism were mainly 
related to one of two aspects, i.e. nutritional adequacy [25, 55, 56] or physical development [57]. 
Three studies related to nutritional adequacy investigated possible deficiencies of children on 
restriction diets as compared to healthy control children or children with autism on unrestricted 
diets.  Two  of  these  studies  tried  to  estimate  adequacy  from  dietary  records  documented  by 
parents  and  did  not  find  evidence  for  any  more  nutritional  deficiencies  as  in  respective 
comparison  groups  [25,  56].  The  third  study  found  deficiencies  in  plasma-derived  levels  of 
essential  amino  acids  including  important  neurotransmitter  precursors  such  as  tyrosine  and Functional Foods in Health and Disease 2014; 4(8):349-361                                                            Page 356 of 361 
 
 
tryptophan [55]. A study by Hediger et al. (2008) [57] was concerned with physical development 
and compared the bone cortical thickness of children with autism on a casein-free diet (with a 
resultant low intake of calcium) with those on unrestricted diets and with reference values. These 
authors found that the children with autism showed a reduction in bone cortical thickness; the 
reduction  was  significantly  more  pronounced  in  the  group  on  a  casein-free  diet  [57].  These 
aspects should be considered more thoroughly and on a routine basis in future studies of GFCF 
dietary effects. 
 
Concluding Remarks and Future Directions 
The scientific evaluation of long-term and high-effort dietary interventions such as the GFCF 
diet is no easy-to-manage task. There are many methodological problems which have to be met 
by adequate research designs which might not be available due to practical or financial reasons. 
Based on the above mentioned methodological shortcomings of existing studies and conceptual 
issues  related  to  the  GFCF  diet,  recommendations  for  future  dietary  studies  include  the 
implementation of adequate control procedures for single case or group research studies, the use 
of  standardized  assessment  instruments  in  intervention  studies  in  autism  and  the  choice  of 
adequate trial durations and of a wider range of measures. 
The scientific basis regarding the efficacy of the GFCF diet in the treatment of autism is 
very  sparse  and  cannot  even  be  judged  as  promising.  Despite  the  diet’s  popularity  as  a 
supplementary  treatment,  its  widespread  use  (according  to  the  prevalence  studies)  and  the 
positive views of parents regarding its effects, most of the more rigorous scientific evaluations 
failed to confirm these observations. There is a large number of seriously flawed studies and the 
few  methodologically  acceptable  studies  conducted  to  date  do  not  allow  firm  conclusions 
concerning  the  diet’s  efficacy.  The  establishment  of  a  clear  link  between  the  diet’s 
implementation  and  positive  effects  on  autistic  symptoms  would  be  a  major  step  in  the 
evaluation  of  the  “opioid  excess  theory”.  A  scientifically  sound  evaluation  of  this  theory  is 
currently impossible on the basis of published research.  
In recent years, other studies conducted within the framework of the “opioid excess theory” 
failed to confirm some of the theory’s major predictions, e.g. the detection of heightened urinary 
(opioid) peptide levels [48, 51, 58-60]. These observations also weaken the underlying rationale 
for the recommendation and use of the GFCF diet as a direct and compensatory treatment of the 
hypothesized  etiology  of  autism.  Nevertheless,  future  dietary  studies  in  this  area  should 
implement  methodologically  sound  designs  in  order  to  establish  more  convincing  evidence 
regarding dietary effects.  
Although the dietary studies performed so far do not seem to confirm the predictions of the 
“opioid excess theory” and the conceptualization of autism as a metabolic disorder, the case of 
nutrition in autism should not be closed preemptively. As there is increasing evidence of possible 
links between gut anomalies and the autistic brain [61], which also point to the importance of 
immunological factors and their role in the frequently observed gastrointestinal disturbances in 
autistic  children,  the  consideration  of  gluten/casein  and  other  dietary  factors  should  not  be 
rejected prematurely in autism research. The conceptualization of autism as an immunological 
disorder  could  explain  multiple  environmentally-mediated  pathways  leading  to  autistic Functional Foods in Health and Disease 2014; 4(8):349-361                                                            Page 357 of 361 
 
 
symptoms. Within such a theoretical model, gluten/casein and other food-derived proteins might 
play  a  role  in  triggering  allergic  responses,  which  might  have  some  influence  on  brain 
development  and  function  by  exerting  direct  influence  upon  neuronal  function  [see  61]. 
Although  the  literature  regarding  possible  links  between  autism  and  allergic  reactions  to 
gluten/casein is promising [62, 63, 64], there is a need for more scientific studies investigating 
the role of nutrition in the etiology and treatment of autism. 
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